In the wake of recent Foreign Corrupt Practices Act (FCPA) enforcement actions initiated by the Department of Justice (DOJ), U.S. companies are scrambling to reevaluate their existing anti-bribery policies. The latest cases involve notable decisions to not prosecute, most prominently seen with a U.S. biotech firm and its subsidiaries. The November 16, 2023, declination letter in these cases offers wise lessons for corporations keen on shielding themselves from the repercussions of employees who defy internal anti-bribery regulations.
While it might appear that the DOJ is escalating its activities against U.S. firms, the true narrative is more nuanced; the goal isn’t simply to nab as many companies as possible on FCPA violations. Rather, focus appears to lie on encouraging businesses to proactively design and implement anti-bribery policies that actively prevent any potential missteps.
The recent declination letters demonstrate that companies can, and do, avoid prosecution, provided they take the appropriate measures. The DOJ, therefore, is sending a clear-cut message: proper planning and swift action can make all the difference when it comes to circumventing FCPA prosecution.
Ultimately, it is incumbent on the individual organization to identify vulnerabilities within their company and address them immediately through comprehensive anti-bribery policies. These policies should be designed to not only protect the organization but to also foster a culture of integrity and accountability.
The fact that certain companies have been spared prosecution clearly communicates the DOJ’s commitment to recognizing good faith efforts by corporations to prevent corruption. This ought to serve as an incentive for other companies to follow suit by implementing rigorous anti-bribery systems, ensuring both compliance and good corporate governance.